Intimation of the Outcome of Board Meeting Scheduled to be held on 14th November, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 5.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Asston Pharmaceuticals' board, meeting on 14th November 2025, approved unaudited H1 FY26 results (ended 30 Sept 2025) and a major capacity expansion. Total income surged to Rs 1,690.30 lakhs from Rs 900.16 lakhs in H1 FY25, roughly 88% year-on-year growth. However, net profit for the period came in at just Rs 3.40 lakhs versus Rs 195.17 lakhs last year, as a Rs 334.82 lakh exceptional charge for IPO expenses wiped out most of the operating profit. The company also announced a new manufacturing unit (Unit II) at MIDC Ambernath, raising tablet-making capacity from 5-6 crore to 14-15 crore per month (nearly 2.5x), backed by ~Rs 600 lakhs from internal accruals and IPO proceeds, to be operational by Q4 FY26.
Strong top-line growth and a significant capacity expansion signal confidence in future demand, but the sharp drop in bottom-line profit (due to one-time IPO costs) and deeply negative operating cash flow of Rs -1,034.54 lakhs may concern short-term investors. Capacity ramp-up by Q4 FY26 could drive revenue and earnings growth once IPO-related costs fade.